-
Wogonin, NETs, and CCL2 in Atopic Dermatitis
2026-10-10
A 2026 study links wogonin’s anti-inflammatory activity in atopic dermatitis models to a miR-4667-5p/CCL2 pathway that connects keratinocyte dysfunction with neutrophil extracellular trap formation. Its combined cellular, animal, network-biology, and molecular-interaction evidence supports a mechanistic hypothesis, while model limitations mean the findings are not yet clinical evidence.
-
ETS1, SUMOylation, and Mitophagy in BPD
2026-10-09
A 2026 study identifies ETS1 as a transcriptional regulator of the SENP2/HSPA8/FUNDC1 pathway in hyperoxia-associated bronchopulmonary dysplasia models. Its findings connect SUMO1-dependent control of FUNDC1 turnover with mitochondrial damage and excessive mitophagy, while remaining limited to preclinical cell and mouse evidence.
-
Melittin in GPCR and GBM Signaling Research
2026-10-09
Melittin is a bioactive peptide described by the supplier as a modulator of Gs and Gi protein activity. This article separates that product-level description from peer-reviewed glioblastoma evidence involving the miR-18a–ALOXE3–12-HETE axis, ferroptosis, migration, and Gs-protein-coupled receptor signaling.
-
CCK-8 and Translational Biology in Ulcerative Colitis
2026-10-08
Plant-derived extracellular vesicle-like particles may improve budesonide delivery for ulcerative colitis, but translational confidence depends on separating cytocompatibility, metabolic activity, uptake, inflammatory signaling, and disease-level efficacy. This article examines how Cell Counting Kit-8 (CCK-8) can contribute to that evidence architecture while clarifying what a WST-8-based viability readout can—and cannot—establish.
-
4-Ethylphenyl Sulfate: Evidence and Research Context
2026-10-08
4-Ethylphenyl sulfate, also called 4-ethylphenyl hydrogen sulfate, is discussed in renal dysfunction and gut microbiota–brain interaction research. Available evidence supports its value as a research hypothesis and analytical target, but the supplied sources do not establish clinical biomarker validity, causal neurological effects, or therapeutic utility.
-
Bestatin and Angiotensin Signaling in Rat Brain
2026-10-07
The 1987 Brain Research study by Harding and Felix used complementary aminopeptidase inhibitors and angiotensin analogs to test whether angiotensin II must be converted to angiotensin III before activating rat brain neurons. Its pharmacological evidence supports an essential processing step, while also showing that bestatin can enhance responses to both peptides, indicating that aminopeptidase effects are not limited to peptide formation.
-
Aconitase Activity Colorimetric Assay Kit in T Cells
2026-10-07
Explore how the Aconitase Activity Colorimetric Assay Kit can complement CD8+ T-cell immunometabolism studies without overstating what an aconitase readout proves. This article connects iron-sulfur enzyme activity, oxidative damage measurement, and the CD28-ARS2-PKM findings reported by Holling et al.
-
L-Phenylephrine: A Sex-Aware α1A Signaling Guide
2026-10-06
L-Phenylephrine is an adrenergic α1A receptor agonist whose effects depend on receptor context, tissue state, and physiological sex. This evidence-focused guide connects its cardiovascular, neural, and airway research uses with a critical interpretation of sex differences in angiotensin II hypertension.
-
CGF, ROS, and Cell-Cycle Arrest in Colorectal Cancer
2026-10-06
Jiang et al. identify Cya-Gly-Fer (CGF), an anthocyanin derivative from purple sweet potato, as a candidate compound that suppresses colorectal cancer through metabolic and mitochondrial stress. Their multi-model study connects ABC transporter disruption, ATP accumulation, ROS overload, MAPK/ERK1/2/c-MYC suppression, cell-cycle arrest, and apoptosis, while also highlighting important limits to clinical interpretation.
-
Erastin: Mechanism, Evidence, and Limits
2026-10-05
Erastin is a ferroptosis inducer used to study cystine limitation, glutathione loss, and oxidative cell death. Evidence supports a context-dependent relationship with RAS-RAF-MEK signaling, but product specifications and historical cell-model findings do not establish universal tumor selectivity.
-
NMDA in Glaucoma Research: BMP4-GPX4 Evidence
2026-10-04
A source-grounded overview of how NMDA (N-methyl-D-aspartic acid) is used conceptually in excitotoxicity research, what the 2025 BMP4-GPX4 glaucoma study reported, and where the evidence remains limited.
-
Cyanidin Chloride: Evidence and Research Context
2026-10-03
Cyanidin Chloride is an anthocyanin polyphenolic antioxidant of interest in redox, inflammatory, and epithelial-barrier research. A 2024 cell-model study reported radical-scavenging, anti-inflammatory, and barrier-associated effects for a material identified as cyanin chloride. However, nomenclature and molecular-identity differences limit direct attribution to cyanidin chloride, and no supplied evidence establishes clinical benefit or activity in human psoriasis.
-
L-Threonine for Metabolic Assay Workflows
2026-10-02
Use L-Threonine to define amino-acid availability in cell culture, metabolic profiling, and nutritional intervention studies while keeping alkaline phosphatase measurements analytically controlled. This workflow pairs a tunable biological nutrient context with a metal-free nanozyme detection concept, separating metabolic effects from assay chemistry.
-
ECL Chemiluminescent Substrate Detection Kit Workflow
2026-10-01
Build reproducible HRP-based Western blot, immunoassay, and membrane-probe workflows with practical exposure and troubleshooting guidance. The workflow also translates mechanistic findings on wogonin, NETs, miR-4667-5p, and CCL2 into actionable protein-validation experiments.
-
Notch Spatial Interactomes Reveal Ataxin-2 Recycling
2026-10-01
Bian et al. used TurboID proximity-labeling proteomics to map human NOTCH receptor interaction networks according to subcellular location. The study identifies ER-Golgi intermediate compartment storage and Ataxin-2-dependent rapid recycling as mechanisms that maintain Notch signaling readiness, offering a framework for studying receptor trafficking in leukemia and other Notch-associated diseases.